|
|
|
|
|
Highlights from the 2022 American Society of Clinical Oncology Annual Meeting |
|
|
|
|
| Best Approaches and Updates for Prostate Cancer Biochemical Recurrence
|
|
| Salvage Treatment for Biochemical Recurrence After Radical Prostatectomy |
| Chris C. Parker, MD, FRCR |
| Chris Parker discussed salvage treatment for biochemical failure after radical prostatectomy. According to Dr. Parker, there are four discussion points with regards to salvage treatment for biochemical failure after radical prostatectomy: (i) salvage radiotherapy dose, (ii) salvage radiotherapy target volume, (iii) use of ADT with salvage radiotherapy, and (iv) timing of salvage radiotherapy. |
|
|
|
|
|
| Molecular-Based Imaging Redefining the Disease Landscape
|
| Thomas A. Hope, MD
|
| At the 2022 American Society of Clinical Oncology Annual Meeting held in Chicago and virtually, a breakout session assessing the best approaches and treatment updates in biochemically recurrent prostate cancer featured a presentation from Dr. Thomas A. Hope discussing the manner in which molecular-based imaging is defining the landscape of prostate cancer.
|
|
|
|
|
|
| Reimaging the Timing and Intensity of ADT in Biochemical Recurrence
|
| Channing J. Paller, MD
|
| Channing Paller discussed questions related to the timing and intensity of androgen deprivation therapy (ADT) in biochemical recurrence of prostate cancer. Dr. Paller noted that biochemical recurrence is common. While PSA is critical for diagnosing BCR, it should not be the only factor considered in determining treatment approach. The risks and benefits of treatment should be considered when initiating ADT.
|
|
|
|
|
|
| Moving Beyond TKI and Immuno-oncology in Renal Cell Carcinoma - Discussion |
| Anil Kapoor, BSc, BEngr, MD, FRCS |
| The 2022 ASCO annual meeting included a poster discussion session for kidney and bladder cancer, including a discussant presentation from Dr. Anil Kapoor discussing moving beyond TKI and immune-oncology in renal cell carcinoma (RCC). |
|
|
|
|
|
|
|
|
|
|
| Poster Session and Discussions: Genitourinary Cancer--Kidney and Bladder
|
|
| Perioperative Chemoimmunotherapy With Durvalumab for Operable Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single Arm Phase II Trial SAKK 06/17 |
| Richard Cathomas, MD |
| Richard Cathomas discussed the role of peri-operative chemoimmunotherapy for patients undergoing radical cystectomy for muscle invasive urothelial carcinoma based on the SAKK 06/17 trial. Based on the data, the addition of perioperative durvalumab to the standard of care neoadjuvant chemotherapy and surgical resection for patients with resectable MIUC results in a high EFS, RFS and OS at 2 years, particularly among those patients with downstaging following neoadjuvant therapy. |
|
|
|
|
|
| Long-Term Outcomes in EV-301: 24-Month Findings From the Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma |
| Jonathan Rosenberg, MD |
| Jonathan Rosenberg examined the long-term outcomes of enfortumab vedotin (EV) in patients with previously treated advanced urothelial carcinoma (UC) in the EV-301 trial. EV continues to show a significant and consistent survival advantage over standard chemotherapy in patients with previously treated locally advanced and metastatic UC, without evidence of new safety signals over longer follow-up. |
|
|
|
|
|
| Avelumab As the Basis of Neoadjuvant Regimen in Platinum-Eligible and -Ineligible Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: AURA (Oncodistinct-004) Trial
|
| Nieves Martinez Chanza, MD, Ph.D.
|
| Nieves Chanza discussed the role of avelumab as a neoadjuvant treatment in patients with non-metastatic muscle invasive bladder cancer (MIBC). In this group of cisplatin-ineligible patients, neoadjuvant avelumab monotherapy resulted in high pCR and was safely administered without compromising surgical resection. Further follow-up of this cohort is ongoing.
|
|
|
|
|
|
| Improving Outcomes Across the Stages in Bladder Cancer - Discussion |
| Matthew Milowsky, MD, FASCO |
| Following three abstract presentations in the poster discussion session focused on Kidney and Bladder cancers at the 2022 American Society of Clinical Oncology Annual Meeting held in Chicago and virtually, Dr. Matthew I. Milowsky provided a discussion of how these data can help us understand to how we may improve outcomes for patients with bladder cancer across its natural history and many stages. |
|
|
|
|
|
| Preliminary Results from Phase Ib/II Neoadjuvant CG0070 and Nivolumab for Cisplatin -Ineligible Muscle Invasive Bladder Cancer
|
| Roger Li, MD
|
| Roger Li discussed the role of neoadjuvant CG0070 and nivolumab as neoadjuvant therapy in patients with muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. The authors conclude that neoadjuvant CG0070 and nivolumab is safe and effective in cisplatin-ineligible patients with MIBC.
|
|
|
|
|
|
| Defining “Platinum-Ineligible” Patients with Metastatic Urothelial Cancer
|
| Shilpa Gupta, MD
|
| Shilpa Gupta discussed how we define platinum eligibility for patients with metastatic urothelial carcinoma. While the treatment landscape has changed significantly for patients with metastatic UC who are ineligible for cisplatin, a platinum-based chemotherapy regime remains the most efficacious treatment approach for patients with advanced UC. Currently, the preferred standard for patients deemed cisplatin ineligible is carboplatin and gemcitabine followed by avelumab.
|
|
|
|
|
|
| Interim Results from a Multicenter Clinical Study of Tislelizumab Combined with Gemcitabine and Cisplatin as Neoadjuvant Therapy for Patients with cT2-T4aN0M0 MIBC |
| Tianxin Lin |
| Tianxin Lin examined novel neoadjuvant treatment approaches for patients with localized muscle invasive bladder cancer (MIBC). Neoadjuvant tislelizumab combined with gemcitabine and cisplatin showed promising anti-tumor activity with high pCR and good tolerability in patients with MIBC. Based on these favourable results from the first-stage, this trial is continuing enrollment. |
|
|
|
|
|
| Evaluating Oncologists’ Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): The U.S. Physician PARADIGM Study (Part 2) |
| Frank Liu |
| Frank Liu discussed practice patients and decision making considerations in locally advanced or metastatic urothelial carcinoma (la/mUC) among practicing US-based oncologists. There is considerable variability in physician attitudes towards first-line treatment and first-line maintenance therapy in metastatic UC, despite several physician characteristics being associated with this treatment patterns. |
|
|
|
|
|
|
|
|
|
|
| Pembrolizumab + Axitinib Versus Sunitinib As First-Line Therapy for Advanced Clear Cell RCC: Analysis of Progression After First Subsequent Therapy in KEYNOTE-426 |
| Thomas Powles, MBBS, MRCP, MD |
| Tom Powles discussed an analysis of progression after first subsequent therapy in KEYNOTE-426, which tested pembrolizumab + axitinib versus sunitinib as first-line therapy for advanced clear cell RCC. Results from this exploratory analysis of PFS2 support the long-term benefit of pembrolizumab + axitinib as first-line treatment for patients with advanced clear cell RCC. |
|
|
|
|
|
| Sequencing Challenges in Renal Cell Carcinoma: What to Do Next? - Discussion |
| Cristina Suarez, MD |
| Cristina Suarez discussed several abstracts which included “Adjuvant pembrolizumab for post-nephrectomy RCC: Expanded efficacy analyses from KEYNOTE-564” presented by Dr. Toni Choueiri, “Pembrolizumab + axitinib versus sunitinib as first-line therapy for advanced clear cell RCC: Analysis of progression after first subsequent therapy in KEYNOTE-426” presented by Dr. Tom Powles, and “Impact of subsequent therapies in patients with advanced RCC receiving lenvatinib + pembrolizumab or sunitinib in the CLEAR study” presented by Dr. Martin Voss. |
|
|
|
|
|
| Preliminary Results of a Phase Ib/II Combination Study of RC48-ADC, a Novel Humanized Anti-HER2 Antibody-Drug Conjugate With Toripalimab, a Humanized IgG4 mAb Against PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma |
| Xinan Sheng, MD, ABFT
|
Xinan Sheng presented on the role of combined treatment of advanced urothelial carcinoma (UC) using a combination of a HER-2 targeted antibody-drug conjugate and immunotherapy. These data form the basis for an ongoing randomized comparison of first-line RC48-ADC and toripalimab compared to standard of care platinum-based chemotherapy in patients with previously untreated locally advanced or metastatic UC.
|
|
|
|
|
|
| A Phase II Study of RC48-ADC in HER2-Negative Patients With Locally Advanced or Metastatic Urothelial Carcinoma |
| Huayan Xu, MD |
Huayan Xu presented on the role of combined treatment of advanced urothelial carcinoma (UC) using a combination of a HER-2 targeted antibody-drug conjugate and immunotherapy. The authors conclude that this phase II trial demonstrates that RC-48-ADC is safe and has evidence of activity in HER-negative patients with locally advanced or metastatic urothelial carcinoma.
|
|
|
|
|
|
| RC48-ADC For Metastatic Urothelial Carcinoma With HER2-Positive: Combined Analysis of RC48-C005 and RC48-C009 Trials
|
| Xinan Sheng, MD, ABFT
|
| Xinan Sheng presented on the role of combined treatment of advanced urothelial carcinoma (UC) using a combination of a HER-2 targeted antibody-drug conjugate and immunotherapy. RC48-ADC monotherapy showed a promising efficacy with a manageable safety profile in HER2-positive patients with metastatic UC who progressed following at least one line of systemic chemotherapy.
|
|
|
|
|
|
| HER-2 Is New Again in Bladder Cancer - Discussion
|
| Matthew Galsky, MD
|
| Following three abstract presentations in the poster discussion session focused on Kidney and Bladder cancers at the 2022 American Society of Clinical Oncology Annual Meeting held in Chicago and virtually, Dr. Matt D. Galsky provided a discussion of HER-2 in bladder cancer though he added the subtitle “there are no bad targets… just suboptimal approaches”.
|
|
|
|
|
|
 |
